By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...
By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...
Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...
Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery technology, which enables the safe and effective delivery of nucleic acid ...
Moderna has filed a lawsuit against Pfizer and its German partner BioNTech for allegedly copying their COVID-19 vaccine. On Friday, Moderna issued a news release accusing Pfizer of infringing several ...
BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...
Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
Moderna, Inc. settles LNP patent dispute for $950M, securing royalty-free tech access and legal clarity; click for what it ...
Pfizer’s mRNA flu shot prevented more flu-like illness than a standard vaccine More than 18,000 adults took part in the study Side effects were mild and went away quickly FRIDAY, Nov. 21, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results